NORTRIPTYLINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nortriptyline Hydrochloride, and what generic alternatives are available?
Nortriptyline Hydrochloride is a drug marketed by Ani Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Rising, Taro, Teva, Zydus Lifesciences, Pharm Assoc, and Rubicon. and is included in eleven NDAs.
The generic ingredient in NORTRIPTYLINE HYDROCHLORIDE is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nortriptyline Hydrochloride
A generic version of NORTRIPTYLINE HYDROCHLORIDE was approved as nortriptyline hydrochloride by DR REDDYS LABS SA on March 30th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORTRIPTYLINE HYDROCHLORIDE?
- What are the global sales for NORTRIPTYLINE HYDROCHLORIDE?
- What is Average Wholesale Price for NORTRIPTYLINE HYDROCHLORIDE?
Summary for NORTRIPTYLINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 27 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Clinical Trials: | 50 |
Patent Applications: | 1,473 |
DailyMed Link: | NORTRIPTYLINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NORTRIPTYLINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chang Gung Memorial Hospital | Phase 2 |
Assiut University | N/A |
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude | Phase 2 |
Pharmacology for NORTRIPTYLINE HYDROCHLORIDE
Drug Class | Tricyclic Antidepressant |